Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan A Fallowfield

Showing results (41-50 of 68) with videos related to

Pageof 7
Sort By:
Hepatology (Baltimore, Md.)|January 7, 2012
Elastin accumulation is regulated at the level of degradation by macrophage metalloelastase (MMP-12) during experimental liver fibrosisAntonella Pellicoro, Rebecca L Aucott, Prakash Ramachandran, et al.
BMC Cancer|September 14, 2018
Study protocol: HepaT1ca - an observational clinical cohort study to quantify liver health in surgical candidates for liver malignanciesDamian J Mole, Jonathan A Fallowfield, Timothy J Kendall, et al.
Biology Open|June 20, 2018
Non-invasive assessment of liver disease in rats using multiparametric magnetic resonance imaging: a feasibility studyAnna M Hoy, Natasha McDonald, Ross J Lennen, et al.
Obesity Science & Practice|October 11, 2021
Addition of hyaluronic acid to the FIB-4 liver fibrosis score improves prediction of incident cirrhosis and hepatocellular carcinoma in type 2 diabetes: The Edinburgh Type 2 Diabetes StudySheila M Grecian, Stela McLachlan, Jonathan A Fallowfield, et al.
Stem Cell Research & Therapy|March 12, 2025
Hormone correction of dysfunctional metabolic gene expression in stem cell-derived liver tissueAlvile Kasarinaite, Maria Jimenez Ramos, Mariana Beltran-Sierra, et al.
Clinical Epigenetics|August 5, 2025
Gradual DNA methylation changes reveal transcription factors implicated in metabolic dysfunction-associated steatotic liver disease progression and epigenetic age accelerationEvelien Van Dijck, Steven Van Laere, Emilie Logie, et al.
The Lancet. Gastroenterology & Hepatology|March 1, 2024
Progress is impossible without change: understanding the evolving nomenclature of steatotic liver disease and its effect on hepatology practicePaul N Brennan, Oliver D Tavabie, Wenhao Li, et al.
Scientific Reports|September 9, 2017
In search of a small molecule agonist of the relaxin receptor RXFP1 for the treatment of liver fibrosisAndrew McBride, Anna M Hoy, Mark J Bamford, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 9, 2020
Non-invasive risk scores do not reliably identify future cirrhosis or hepatocellular carcinoma in Type 2 diabetes: The Edinburgh type 2 diabetes studySheila M Grecian, Stela McLachlan, Jonathan A Fallowfield, et al.
Hepatology (Baltimore, Md.)|July 23, 2013
Relaxin modulates human and rat hepatic myofibroblast function and ameliorates portal hypertension in vivoJonathan A Fallowfield, Annette L Hayden, Victoria K Snowdon, et al.
Pageof 7

Showing results (41-50 of 68) with videos related to

Sort By:
Pageof 7
Hepatology (Baltimore, Md.)|January 7, 2012
Elastin accumulation is regulated at the level of degradation by macrophage metalloelastase (MMP-12) during experimental liver fibrosisAntonella Pellicoro, Rebecca L Aucott, Prakash Ramachandran, et al.
BMC Cancer|September 14, 2018
Study protocol: HepaT1ca - an observational clinical cohort study to quantify liver health in surgical candidates for liver malignanciesDamian J Mole, Jonathan A Fallowfield, Timothy J Kendall, et al.
Biology Open|June 20, 2018
Non-invasive assessment of liver disease in rats using multiparametric magnetic resonance imaging: a feasibility studyAnna M Hoy, Natasha McDonald, Ross J Lennen, et al.
Obesity Science & Practice|October 11, 2021
Addition of hyaluronic acid to the FIB-4 liver fibrosis score improves prediction of incident cirrhosis and hepatocellular carcinoma in type 2 diabetes: The Edinburgh Type 2 Diabetes StudySheila M Grecian, Stela McLachlan, Jonathan A Fallowfield, et al.
Stem Cell Research & Therapy|March 12, 2025
Hormone correction of dysfunctional metabolic gene expression in stem cell-derived liver tissueAlvile Kasarinaite, Maria Jimenez Ramos, Mariana Beltran-Sierra, et al.
Clinical Epigenetics|August 5, 2025
Gradual DNA methylation changes reveal transcription factors implicated in metabolic dysfunction-associated steatotic liver disease progression and epigenetic age accelerationEvelien Van Dijck, Steven Van Laere, Emilie Logie, et al.
The Lancet. Gastroenterology & Hepatology|March 1, 2024
Progress is impossible without change: understanding the evolving nomenclature of steatotic liver disease and its effect on hepatology practicePaul N Brennan, Oliver D Tavabie, Wenhao Li, et al.
Scientific Reports|September 9, 2017
In search of a small molecule agonist of the relaxin receptor RXFP1 for the treatment of liver fibrosisAndrew McBride, Anna M Hoy, Mark J Bamford, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 9, 2020
Non-invasive risk scores do not reliably identify future cirrhosis or hepatocellular carcinoma in Type 2 diabetes: The Edinburgh type 2 diabetes studySheila M Grecian, Stela McLachlan, Jonathan A Fallowfield, et al.
Hepatology (Baltimore, Md.)|July 23, 2013
Relaxin modulates human and rat hepatic myofibroblast function and ameliorates portal hypertension in vivoJonathan A Fallowfield, Annette L Hayden, Victoria K Snowdon, et al.
Pageof 7